RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087

Curr Med Res Opin. 2020 Jul;36(7):1125-1127. doi: 10.1080/03007995.2020.1744549. Epub 2020 Apr 7.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Antibodies, Bispecific*
  • Antibodies, Monoclonal, Humanized
  • Factor VIII
  • Hemophilia A* / drug therapy
  • Humans
  • Network Meta-Analysis

Substances

  • Antibodies, Bispecific
  • Antibodies, Monoclonal, Humanized
  • emicizumab
  • Factor VIII